On one hand, numerous studies have proven that tumor necrosis factor receptor-associated factor 6 (TRAF6) might be a plausible therapeutic target that suppresses osteoblastic differentiation in the BMP2-mediated ectopic ossification of OPLL (Tsukahara et al., 2006). The gene discussed is BMP2; the disease is ossification of the posterior longitudinal ligament of the spine.